Therapeutic efficacy of recombinant human leukemia inhibitory factor in a
primate model of radiation-induced marrow aplasia
AM Farese, LA Myers and TJ MacVittie
Armed Forces Radiobiology, Research Institute, Bethesda, MD 20889-5603.
The therapeutic efficacy of recombinant human leukemia inhibitory factor
(LIF) was examined in a nonhuman primate model of radiation- induced marrow
aplasia. Rhesus monkeys received 450 cGy of total-body, 1:1 mixed
neutron:gamma radiation. For 23 days thereafter, each monkey received a
daily subcutaneous injection of LIF or human serum albumin (HSA) at a dose
of 15 micrograms/kg body weight. Complete blood counts and white blood cell
differentials were monitored for 60 days postirradiation. Administration of
LIF significantly decreased (P < or = .05) the duration of
thrombocytopenia (platelet count < 30,000 or 20,000/microL), ie, 9.3
days or 6.3 days, respectively, versus the HSA- treated control monkeys,
12.2 days or 10.2 days, respectively. Treatment with LIF did not alter the
duration of neutropenia (absolute neutrophil count < 1,000/microL) as
compared with the HSA-treated control monkeys. Cytokine administration did
not exacerbate the radiation-induced anemia observed in the HSA-treated
control monkeys.
Volume 84,
Issue 11,
pp. 3675-3678,
12/01/1994
Copyright © 1994 by The American Society of Hematology
